+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Medical Device Development: Regulation and Law 2014

  • Book

  • 600 Pages
  • June 2014
  • Cambridge Healthtech Institute
  • ID: 2858653
The 'Medical Device Development: Regulation and Law, 2014 Edition' is the 'must-have' resource for the novice or veteran medical device regulatory affairs professional. This practical reference provides the most comprehensive and updated analysis of US medical device and diagnostics development and approval requirements anywhere.

Since the 2009 edition of this book, new device legislation has been enacted and FDA has issued over a dozen or more important new guidances. The 2014 edition features in-depth analysis of these developments, and addresses how emerging developments and trends are reshaping medical device and combination product regulations in the US.


“I have been in the regulatory affairs profession for over 23 years now… Mr. Kahan has done an admirable job in creating this book, and I am thankful to have it on my desk for easy reference when needed.”
Tamima Itani, Ph.D., FRAPS, RAC Vice President, Global Regulatory Affairs and Regulatory Compliance, Boston Scientific

"This is one of the best books written on the subject of regulatory affairs for the medical device industry. This book is a great tool whether you are a seasoned regulatory professional or a front line supervisor. Kahan is in my opinion on his way to becoming the Juran of the regulatory field."
Scott Baker, CQT, CQE, CQA, Supplier Quality Engineer II, Smith & Nephew, Inc.

Table of Contents

The 2014 edition of this popular and authoritative resource reviews and analyzes the following critical developments since the 2009 edition:

- Update on all the new provisions of the Food and Drug Administration Safety and Improvement Act of 2012 (FDASIA).

- New statutory provisions and guidances on device reclassification, including provisions relating to the direct de novo petition and reclassification by administrative order.

- New statutory provisions and guidances related to humanitarian devices, including new rules on making profits on humanitarian devices and approvals for pediatric indications.

- New statutory provisions and guidances on the CDRH appeal process, including procedures for appeal of “significant decisions.”

- New statutory provisions and guidances on Section 522 postmarket surveillance orders.

- New statutory provisions and requirements on custom devices, including the new “five times replication” rule.

- New statutory provisions and guidances related to mobile medical apps and medical device software, including medical data software systems.

- Updates on the new organizational structure of CDRH, including revisions to the structure of the Office of Device Evaluation the Office of Compliance, and the Office of In Vitro Diagnostics and Radiological Health.

- Changes to the 510(k) premarket notification process, including new policies on split predicates, when a device cannot be found to be SE, and the new priority review guidance.

- Changes to the pre-submission process, including the end of the pre-IDE process and the birth of the “Q-sub.”

- New guidances on FDA's “Refusal to Accept” policies relating to 510(k)s, PMA's, and pre-submissions.

- Update on the investigational device exemption process, including new guidances on early feasibility studies, FDA decisions for IDE investigations, design considerations for pivotal clinical device investigations, and good laboratory practices.

- Changes to the premarket approval application process, including birth of the e-copy and modifications to the advisory panel process

- New policies and guidances concerning in vitro diagnostic products, including the new guidances on Research Use Only (RUO)/Investigational Use Only (IUO) products, and in vitro “companion” diagnostics.

- Update on device compliance issues, including the 2013 draft medical device reporting guidance and recall procedures relating to product enhancements.

- New guidances and cases relating to combination products incorporating medical devices.


The book is written by Jonathan S. Kahan, Partner, Hogan Lovells US LLP in Washington, D.C. Jon is a co-director of the firm's food, drug, medical device, and agriculture group, and has been practicing in FDA law for 40 years. Jon is also an Adjunct Professor at the George Washington University Law School teaching medical device law. His practice focuses primarily on assisting medical device companies in navigating the U.S. Food and Drug Administration (FDA) regulatory process. He also has an extensive practice in combination products, which includes combinations of drugs, devices, and biologics. In addition to the daily counseling of clients in FDA-related matters, he represents many clients in administrative hearings and trials, and in the federal courts. Jon has published numerous law review and other articles concerning FDA regulatory issues.